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Glycopeptide resistance in Staphylococcus aureus is a source of 
great concern because, especially in hospitals, this class of anti-
biotics, particularly vancomycin, is one of the main resources for 
combating infections caused by methicillin-resistant Staphylococ-
cus aureus strains (MRSA).
Reduced susceptibility to vancomycin (VISA) was first described 
in 1996 in Japan; since then, a phenotype with heterogeneous 
resistance to vancomycin (h-VISA) has emerged.
H-VISA isolates are characterised by the presence of a resistant sub-
population, typically at a rate of 1 in 105 organisms, which consti-
tutes the intermediate stage between fully vancomycin-susceptible S. 
aureus (VSSA) and VISA isolates. As VISA phenotypes are almost 
uniformly cross-resistant to teicoplanin, they are also called Glyco-
peptides-intermediate Staphylococcus aureus strains (GISA) and, in 
the case of heterogeneous resistance to glycopeptides, h-GISA.
The overall prevalence of h-VISA is low, accounting for approxi-
mately 1.3% of all MRSA isolates tested.
Mortality due to h-GISA infections is very high (about 70%), 
especially among patients hospitalised in high-risk departments, 
such as intensive care units (ICU).
Given the great clinical relevance of strains that are heteroresist-
ant to glycopeptides and the possible negative impact on treat-
ment choices, it is important to draw up and implement infection 
control practices, including surveillance, the appropriate use of 
isolation precautions, staff training, hand hygiene, environmental 
cleansing and good antibiotic stewardship.
Review
Staphylococcus aureus with reduced susceptibility  
to vancomycin in healthcare settings
A.M. SPAGNOLO, P. ORLANDO, D. PANATTO, D. AMICIZIA, F. PERDELLI, M.L. CRISTINA
Department of Health Sciences, University of Genoa, Italy
Key words
Staphylococcus aureus • MRSA, GISA• h-GISA • Glycopeptide • Vancomycin
Summary
Introduction
Since the 1970s, the selective pressure exerted by an-
tibiotics has given rise to increasingly resistant bacte-
rial species and the last 20 years have seen a marked 
increase in multi-resistant pathogenic strains [1].
Staphylococcus aureus (S. aureus), human commensal 
bacterium involved in an array of pathologies, from mi-
nor dermatological diseases to severe disorders, such as 
pneumonia, endocarditis, meningitis or sepsis, continues 
to be one of the main causes of hospital and community 
infections worldwide [2]. The emergence of resistance 
to penicillin, followed by the spread of strains resistant 
penicillins penicillinases resistant (headed by methicil-
lin, macrolides, tetracyclines, aminoglycosides and, re-
cently, glycopeptides has turned the therapy of staphylo-
coccal infections into a global challenge.
Glycopeptide resistance in S. aureus is a source of great 
concern because, especially in hospitals, this class of an-
tibiotics, particularly vancomycin, is one of the main re-
sources for combating infections caused by methicillin-
resistant S. aureus strains (MRSA).
Methicillin-resistant S. aureus 
The rate of mortality due to S. aureus infections was 
drastically reduced by the introduction of penicillin in 
the early 1940s. A few years later, however, strains of 
S. aureus that had developed plasmid-mediated resist-
ance to penicillin appeared; this resistance was due to 
the production of penicillinase, a ß-lactamase capable of 
breaking down the drug before it could reach its target.
Methicillin, the first semisynthetic penicillin resistant 
to penicillinases, was introduced into clinical practice 
in 1959. This antibiotic proved efficacious in combat-
ing infections due to ß-Lactam antibiotic-resistant S. au-
reus strains until the appearance of methicillin-resistant 
strains of S. aureus, which soon became one of the main 
causes of infection in hospitals. 
The first report of MRSA strains was made in England 
in 1961 [3], not long after the introduction of methicil-
lin, and epidemics caused by MRSA were already be-
ing recorded in the early 1960s [4, 5]. Since then, MR-
SA strains have spread throughout the world and their 
prevalence has increased in both hospital and commu-
nity settings. The epidemiology of MRSA has therefore 
changed in recent years, in that infections are no longer 
confined to the hospital environment, but also involve 
healthy subjects without particular risk factors in the 
community setting [6].
In the USA, MRSA account for more than 60% of all 
S. aureus isolates in intensive care units (ICU)  [7]. In 
Europe, it has been estimated that MRSA cause 171,200 
nosocomial infections each year, corresponding to 44% 
of all hospital infections [8]. In Italy, the percentage of 
MRSA strains isolated in hospitals is around 40%, with 
peaks of up to 80% in some hospitals [9].
A.M. SPAGNOLO et AL.
138
These strains generally display multi-resistance, which 
considerably limits therapeutic options. A study con-
ducted in Canada revealed that the mortality associated 
with bacteraemia due to MRSA was 39%, as opposed to 
24% due to strains of Methicillin-sensitive Staphylococ-
cus aureus (MSSA) [6].
Mechanism of methicillin resistance
All strains of S. aureus produce 4 main membrane pro-
teins capable of binding penicillin and other ß-Lactam 
antibiotics (penicillin-binding proteins, PBP). ß-Lactam 
antibiotics are substrate analogues, which covalently 
bind to the serine-active sites of the penicillin-binding 
proteins (PBPs), inactivating the enzyme at concentra-
tions roughly comparable to the minimum inhibiting 
concentrations (MIC). PBPs 1, 2 and 3, which have a 
high affinity for most ß-Lactam antibiotics, are essen-
tial to the development of the cell and to the survival of 
sensitive strains; the binding of ß-Lactam antibiotics to 
these PBP can kill the bacterial cell [4, 10].
The mecA gene, the expression of which is generally 
regulated by the mecI and mecR1 genes, codifies for 
PBP type 2a (PBP2a), a low-affinity PBP on which re-
sistance itself depends. PBP2a is a 78 kDa protein which, 
in methicillin-resistant strains, owing precisely to its low 
affinity for most ß-Lactam antibiotics, is not saturated 
(and thus functionally blocked) by otherwise lethal con-
centrations of these antibiotics. In such conditions, not 
only does it continue to function, it is also able to vi-
cariously carry out the functions normally performed by 
the other (functionally blocked) high-affinity PBPs [11]. 
The mecA gene (2.1 kb) participates in a broader block 
of DNA (up to 60 kb), called staphylococcal chromo-
somal cassette (SCCmec), containing the determinants 
of resistance to the various non- ß-Lactam antibiotics. 
MecA is normally regulated by the genes mecI (repres-
sion) and mecR1 (induction) [4, 10].
Resistance to glycopeptides and 
epidemiology of h- glycopeptide 
intermediate-resistant S. aureus (GISA) 
strains
Following the global rise in infections caused by mul-
ti-resistant MRSA strains, glycopeptides have become 
the antibiotics of choice for the therapy of nosocomial 
staphylococcal infections in the last 20 years. The glyco-
peptides in clinical use are vancomycin, the co-founder 
drug that came onto the market at the end of the 1950s, 
and teicoplanin, which was introduced into clinical prac-
tice in the second half of the 1980s.
The glycopeptide antibiotics are large rigid molecules, 
which inhibit the last stages of peptidoglycan biosyn-
thesis. Their antimicrobial activity, which is limited to 
Gram-positive bacteria owing to their inability to pen-
etrate the external membrane, is due to their particular 
affinity for the D-alanyl-D-alanine (D-Ala-D-Ala) di-
mer of the lateral chain of the peptidoglycan precursor, 
to which they strongly bind, albeit non-covalently [10]. 
Although this antibiotic has been widely used in the last 
two decades, most MRSA strains are still sensitive to 
vancomycin. Indeed, the first MRSA isolates with re-
duced sensitivity to glycopeptides took about 40 years 
to emerge [12].
The first MRSA isolates displaying reduced sensitiv-
ity to vancomycin (VISA) were reported in Japan in 
1996  [13]; soon afterwards, a phenotype of S. aureus 
with acquired heterogeneous resistance to vancomycin 
(h-VISA) emerged  [14, 15]. h-VISA isolates are char-
acterised by the presence of a subpopulation (1 per 105 
bacterial cells) resistant to vancomycin and represent the 
intermediate stage between total sensitivity to vancomy-
cin (VSSA) and VISA isolates  [10, 16-18]. Following 
the appearance of the first VISA (Mu50) and h-VISA 
(Mu3) strains reported in Japan  [13,  14], both pheno-
types were described worldwide. However, the exact 
prevalence of h-VISA strains is difficult to determine, 
owing to the wide range of methodological tests used, 
of definitions and of modifications in the breakpoints 
of susceptibility to vancomycin. This might explain the 
considerable variability in the prevalence of h-VISA 
strains in the various institutions, geographic regions 
and patient populations.
Very recently, a further phenotype was found and char-
acterized in Mu3-6R-P strain: slow vancomycin-inter-
mediate S. aureus (s-VISA) strains  [19]. h-VISA may 
escape vancomycin therapy temporarily converting into 
s-VISA and later returning to the previous stage as soon 
as therapy is suspended. Therefore, the passage from h-
VISA to s-VISA and viceversa can be interpreted as an 
oscillating, reversible switch mechanism.
Nevertheless, the overall prevalence of h-VISA remains 
low: about 1.3% of all methicillin-resistant Staphylococ-
cus aureus (MRSA) isolates tested [16]. Di Gregorio et 
al. computed h-VISA to be 4.5% of MRSA strains [20]. 
Hanaki and coauthors estimated that h-VISA represent 
6.5% of MRSA strains [21], while Chaudhari and col-
laborators estimated h-VISA to represent 6.9% of 58 
clinical isolates of MRSA [22]. Monaco and coworkers 
carried out a study in order to assess the presence of h-
VISA strains in Italy: they found h-VISA to be 13.6% 
of MRSA strains and 6.1% of all the studied S. aureus 
strains [23].
As VISA strains generally display cross-resistance to 
teicoplanin, they are also called glycopeptide interme-
diate-resistant S. aureus (GISA) [24] and, in the case of 
heteroresistance, h-GISA. In the USA, however, where 
teicoplanin is not available, the terms VISA and h-VISA 
are currently used.
International data from the Tigecycline Evaluation and 
Surveillance Trial (T.E.S.T.) involving 20,004 S. aureus 
isolates show that the proportion of MRSA with vanco-
mycin MICs ≥ 2 mg/L increased from 5.6% in 2004 to 
11.1% in 2009 (P < 0.001) [8]. 
A study conducted in the metropolitan area of Detroit in 
the USA documented a significant increase in the prev-
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alence of h-VISA over 20 years: from 2.27% between 
1986 and 1993 to 8.2% between 2003 and 2006 [25].
VISA strains tend to develop multi-resistance to a large 
number of commonly used antibiotics, thereby deter-
mining a reduction in possible therapeutic options and 
increasing the risk of administering inadequate antibi-
otic therapy [26]. An increase in the resistance of MRSA 
strains leads to increased morbidity and mortality due to 
severe infections such as bacteraemia, endocarditis and 
osteomyelitis [27, 28].
Concern over the development of vancomycin resistance 
in staphylococci is destined to grow dramatically fol-
lowing reports of vancomycin-resistant strains of MR-
SA (VRSA). The first strain was reported in the United 
States in 2002, isolated from a haemodialysis patient; 
this strain proved to be highly resistant to vancomycin 
and was also resistant to teicoplanin. It was isolated 
from the patient together with an enterococcus, VanA, 
and was found to contain in its genome not only the 
mecA gene of methicillin-resistance, but also the vanA 
gene, which is responsible for the most widespread form 
of vancomycin-resistance in enterococci. The DNA 
sequence of the vanA gene of the Staphylococcus was 
identical to that of the vanA gene of the E. faecalis iso-
lated from an infected ulcer in the same patient. This 
strain, the first clinical isolate of S. aureus highly resist-
ant to vancomycin, therefore seems to be the result of 
the spread of VanA resistance from the enterococcus to 
the S. aureus [10, 29]. To date, strains displaying high 
levels of resistance to vancomycin (acquired through the 
vanA gene) are rare, though cases have been reported in 
the USA, India and Iran [8].
The results of a study conducted by Maor [30] revealed 
that 6% of patients affected by MRSA presented h-
VISA strains and that the mortality rate among all the 
h-VISA patients was 75%. This study suggests that h-
VISA infection is associated with unsatisfactory clinical 
outcomes despite the adequate administration of vanco-
mycin.
A study conducted on 86 patients from whom MRSA 
strains with reduced susceptibility to teicoplanin were 
isolated revealed that 3.4% of patients were colonised 
by h-GISA and that 2.5% had bacteraemia caused by h-
GISA. The results of this study suggest that recurrent 
bacteraemia in a patient who has previously undergone 
antibiotic therapy with glycopeptides is an important in-
dicator of the presence of h-GISA [31].
Mortality due to h-GISA infections is very high (about 
70%), especially among patients hospitalised in high-
risk wards, such as intensive care units (ICU), where the 
vulnerability of the patient is exacerbated by such con-
tingencies as invasive medical procedures, the insertion 
of prosthetic devices or of central venous catheters, the 
high frequency of nursing procedures, and the ample use 
of broad-spectrum antibiotic therapy [32].
The hospital environment can play an essential role in 
the transmission of multidrug-resistant pathogens, and 
environmental monitoring can reveal the degree of mi-
crobial contamination  [33]. Environmental contamina-
tion by MRSA strains tends to be very persistent (up to 
38 weeks) [34], which means that surfaces in wards can 
become veritable reservoirs and vehicles for the spread 
of infection  [35, 36]. h-GISA strains are characterised 
by thickening of the peptidoglycan wall [14, 15], which 
is proportional to the degree of resistance to glycopep-
tides; this ultrastructural feature may favour adhesion 
to surfaces, with important implications for the type of 
sanitation measures that need to be implemented.
A study conducted by Perdelli et al. [37] evaluated the 
percentage of MRSA with reduced susceptibility to gly-
copeptides in four ICU by means of environmental sam-
pling of air and representative surfaces. The antibiogram 
performed on the colonies of S. aureus revealed that, in 
the air of the four ICU sampled, 88.8% of the strains 
proved to be resistant to methicillin and that 91.9% of 
these displayed reduced susceptibility to glycopeptides. 
A similar situation emerged with regard to the surfaces 
sampled (72.0% MRSA, 81.1% of which h-GISA).
The prevalence of notified infections due to h-GISA 
strains is low. However, as mentioned previously, this 
might be due to the routine use of laboratory screening 
techniques that have low sensitivity and specificity. It 
would therefore be useful to implement quality controls 
in order to verify the reliability of results and to unmask 
any possible underestimation of the phenomenon [38].
Given the great clinical relevance of strains that are het-
eroresistant to glycopeptides, and their possible negative 
impact on therapeutic choices, measures for prevention 
and control should be implemented both on the clinical 
front and with regard to hygiene/behavior.
Treatment and management
As vancomycin and other glycopeptides, such as te-
icoplanin, have constituted the treatment of choice for 
infections due to MRSA, their excessive use may have 
led to the appearance of h-VISA, VISA and VRSA 
strains. Moreover, it is likely that the true magnitude 
of the problem has been underestimated and that many 
cases of h-VISA, VISA and perhaps VRSA have gone 
undetected owing to the implementation of suboptimal 
screening programs and the shortcomings of current di-
agnostic techniques [30]. As yet, the proportion of MR-
SA strains with reduced susceptibility to vancomycin 
and teicoplanin in the hospital setting is not known [26]. 
Such knowledge, however, would be extremely impor-
tant for the purposes of prevention and control [39], in 
that strains heteroresistant to glycopeptides (h-GISA) 
are the direct precursors of vancomycin-resistant S. au-
reus (VRSA) strains and seem to be directly implicated 
in the failure of antibiotic therapy in MRSA infections 
that spread to deep layers [40, 41].
An alternative to vancomycin is daptomycin, an antibi-
otic belonging to the class of lipopeptides, which dis-
rupts the functioning of the cell membrane through a cal-
cium-dependent bond. Its bactericidal activity depends 
on the concentration. The breakpoint of sensitivity to 
daptomycin for S. aureus is ≤ 1 µg/ml. Non-susceptible 
strains have appeared during treatment with this antibi-
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otic. Although the mechanism of resistance has not been 
clarified, these strains often display point mutations of 
mprF, the gene for lysophosphatidylglycerol synthetase. 
Previous exposure to vancomycin and a high MIC of 
vancomycin have been associated to the increase in the 
MIC of daptomycin, an observation that seems to indi-
cate possible cross-resistance [42].
Prevention and control
In recent years, several international scientific associa-
tions and institutions have drawn up recommendations 
aimed at reducing the spread of MRSA infections in the 
healthcare setting [43-47]. These recommendations are 
concordant with regard to some essential aspects, such 
as the use of specific surveillance tools, the adoption of 
contact precautions (hand hygiene, use of barrier meas-
ures) to limit the spread of any cross-infection, and poli-
cies aimed at promoting the proper use of antibiotics. 
With regard to this last aspect, it is important to ration-
alise the administration and use of glycopeptides in rela-
tion not only to therapeutic results but also to phenom-
ena of resistance.
However, antibiotic policy must not be limited only to 
this class of antibiotics; it must also involve cephalo-
sporins and carbapenems, since the heterogeneous ex-
pression of glycopeptide resistance is also influenced by 
exposure to almost all ß-Lactam antibiotics, even when 
administered at optimal concentrations [15]. The issues 
of the active detection of colonised patients and their de-
colonisation are more controversial [48-53]. This latter 
question has been the subject of recently published sys-
tematic reviews [54, 55]. In 1997, the Centers for Dis-
ease Control and Prevention (CDC) in Atlanta drew up 
a document containing recommendations for preventing 
the spread of vancomycin resistance [56]. Further con-
siderations on the control of infections due to vancomy-
cin-resistant S. aureus strains were made by Wenzel and 
Edmond  [57], particularly with regard to the utility of 
conducting studies on the prevalence of antibiotic resist-
ance, implementing control strategies and, especially, 
contact precautions (hand-washing, use of gloves, isola-
tion, etc.), and immediate notification to the Infections 
Committee of the hospital.
It is also important to utilise appropriate diagnostic 
techniques in order to minimise recourse to prolonged 
empirical therapy; for example to use venous catheters 
only for the time strictly necessary, and to remove pros-
thetic materials infected by S. aureus. It is well known 
that MRSA can spread easily in the hospital environ-
ment, and it is reasonable to suppose that VISA strains 
have the same potential for transmission [10]. Measures 
for the prevention and control of the spread of these 
microorganisms have recently been revised in a docu-
ment endorsed by several European countries. This un-
derscores a few key points: proper hand hygiene and 
routine cleansing and decontamination of environments; 
the use of personal protection devices by healthcare per-
sonnel when attending to MRSA-positive patients; the 
implementation of MRSA surveillance programs, and 
the screening of patients at risk [58]. It has been demon-
strated that controlling the spread of MRSA in hospitals 
requires the simultaneous implementation of both “hori-
zontal” and “vertical” strategies. Horizontal strategies 
are those aimed at preventing the spread of infections 
due to all possible pathogens [37, 59-62] through inter-
ventions such as hand hygiene, environmental cleans-
ing, antibiotic stewardship and proper management of 
vascular catheters; vertical strategies are those aimed at 
controlling a specific pathogen (MRSA)  [63]. An ap-
proach that combines these two strategies – horizontal 
and vertical – can optimise the results [57]. In Italy, the 
Ministry of Health has recently drawn up a document 
which identifies the priority measures to be adopted in 
order to reduce the risk of healthcare-related infections 
(HAIs) caused by MRSA, as indicated in the most recent 
international scientific literature [63]. 
The main measures are listed below:
Surveillance
Organising a system of surveillance is useful only if da-
ta analysis leads to the adoption of suitable provisions. 
Thus, identifying patients infected/colonised by MRSA 
is useful if the system prescribes the subsequent isola-
tion of the positive patient and the implementation of 
contact precautions.
Surveillance can allow the spread of MRSA inside 
health facilities to be detected and monitored over time, 
in order to plan adequate intervention. To ensure optimal 
cooperation on the part of the various departments, sur-
veillance data must be provided periodically.
Handling information on MRSA positivity
The correct and timely transmission of information on 
MRSA positivity is important in order to ensure that the 
necessary interventions and/or decisions be taken to ad-
dress the problem.
At the moment of hospitalisation, the availability of in-
formation on previous colonisation by MRSA can en-
able the patient to be placed pre-emptively in isolation, 
thereby reducing the spread of the microorganism in the 
hospital.
Hand hygiene
Proper hand hygiene is deemed to be the main means 
of reducing HAIs. Compliance with this measure on the 
part of healthcare personnel is generally less than 40%; 
this low percentage has been associated with the use of 
gloves, a practice erroneously regarded as a substitute 
for hand hygiene.
Kapil and collaborators carried out a survey among 
health-care workers (HCWs) and found that 70% had 
bacterial counts ≥ 100 CFUs. Hand hygiene reduced the 
count of 95-99% among doctors and nurses, 70% among 
hospital attendants and 50% among sanitary attendants. 
S. aureus was present on the hands of 8 HCWs of which 
three were MRSA [64]. Similar findings were obtained 
by Monistrol and coworkers who found that S. aureus 
is the most common contaminant in health settings and 
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that, isolated from the hands of healthcare workers, after 
an educational intervention, the MRSA count decreased 
from 1.96 ± 1.2 log10 CFU/ml to 0.89 ± 1.2 log10 CFU/
ml  [65]. Al-Tawfiq and coauthors observed a marked 
decrease in the rate of MRSA cases per 1,000 patient-
days from 0.42 to 0.08, with an increase in the hand hy-
giene compliance [66]. 
82% of patients colonized by MRSA had positive hand 
cultures for MRSA, which reduced after a single appli-
cation of alcohol gel [67]. Besides HCWs hand hygiene 
compliance, also patient hand disinfection plays a major 
role [68].
The use of alcohol gels and solutions for hand hygiene 
has overcome many of the problems of non-compliance, 
especially when time is short owing to heavy workloads.
Contact precautions 
The spread of infections in healthcare facilities is made 
possible by the interaction of three principal elements: 
a source (reservoir) of pathogenic microorganisms; a 
susceptible host and a suitable means of entry for that 
specific microorganism.
The main reservoir of infection is constituted by per-
sons (patients, healthcare workers, visitors and family 
members). Human reservoirs may be subjects who are 
colonised or have active infections. The environment 
may also be involved in the spread of microorganisms, 
through contaminated environmental sources or vehicles 
(equipment, instruments, medical devices, solutions for 
infusion, etc.).
As MRSA is chiefly spread through contact (direct or 
indirect), contact precautions must be taken in order to 
reduce the risk of transmission to a susceptible patient. 
These precautions include: 
•	 isolation	in	a	single	room	or,	if	this	is	not	possible,	
isolation by cohort; 
•	 the	use	of	dedicated	materials;
•	 hand	hygiene;	
•	 the	use	of	disposable	gloves	and	overalls;	
•	 the	use	of	protective	barriers;	
•	 proper	management	of	equipment;	
•	 environmental	hygiene;	
•	 proper	handling	of	bedding	and	crockery;	
•	 healthcare	education,	and	staff	training.	
Environmental hygiene
Healthcare facilities need to draw up regulations for en-
vironmental cleansing (frequency, methods) and to ap-
point a person to be responsible for ensuring that these 
regulations are respected.
The environmental surfaces in healthcare facilities can 
contribute to the spread of cross-infections, in that they 
constitute a possible site for the accumulation of micro-
organisms  [69]. Like medical devices, surfaces must 
therefore be thoroughly cleaned and disinfected regu-
larly; disinfectants must be appropriate and used in con-
formity with the manufacturers’ recommendations and 
the indications of the Hospital Infections Committee, 
and particular attention should be paid to surfaces that 
are touched frequently.
Screening 
In departments with a high incidence of MRSA or in 
those accommodating patients at risk of severe MRSA 
infections, it is advisable to carry out active screening 
of high-risk patients. However, the implementation of 
an MRSA screening system is meaningful only if the 
results of screening are used to enact infection control 
measures.
Decolonisation
Care bundles recommend that nasal decolonisation be 
carried out with mupirocin in all patients identified as 
MRSA-positive, according to the screening strategies 
identified, and skin decolonisation with 4% chlorhex-
idine, 7.5% iodopovidone or 2% triclosan.
Universal decolonization is cost-saving [70] in that pre-
vents 44% of MRSA colonizations and 45% of MRSA 
infections. Also the REDUCE MRSA trial confirmed 
this finding, showing that compared with screening and 
isolation, universal decolonization could save $171,000 
and prevent 9 additional bloodstream infections for eve-
ry 1,000 ICU admissions [71]. 
Personnel
The screening of personal is recommended only when 
there is a strong suspicion that staff may be a source of 
transmission, as in the case of an uncontrolled epidemic. 
Antibiotic stewardship
According to the international recommendations, in or-
der to reduce or at least contain the problem of antibi-
otic resistance, antibiotic policies, such as the following, 
should be implemented: 
1. Avoid inappropriate or excessive antibiotic therapies 
and prophylaxes.
Pay attention to the diagnosis and ensure that the therapy 
is appropriate.
2. Ensure that the dose and duration of antibiotic thera-
py are correct.
3. Reduce as far as possible the use of broad-spectrum 
antibiotics, in particular third-generation cephalo-
sporins and quinolones.
4. Limit the use of glycopeptides and check therapeutic 
levels.
It is also important to check that preoperative antibiotic 
prophylaxis is appropriate in terms of indication, choice 
of drug, dose and duration of prophylaxis, and to moni-
tor the consumption of antibiotics, at least in critical de-
partments at high risk of MRSA.
Antibiotic stewardship is particularly helpful in reduc-
ing MRSA cases and has long-term effect, as shown by 
studies carried out in a secondary-care hospital in Ger-
many [72], and in a tertiary-care teaching hospital in the 
USA [73]. 
It is also important to educate junior doctors about the 
importance of preserving the effectiveness of the avail-
able armamentarium against S. aureus, as demonstrated 
by an interventional study performed at two teaching 
hospitals in France and Scotland [74].
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New strategies and forms of antibiotic stewardship have 
been recently implemented for raising awareness of the 
importance of a correct and proper antibiotic policy 
among the HCWs.
New technologies can help in making antibiotic stew-
ardship highly sustainable, strengthening its impact 
and preserving high quality care while reducing the 
costs [75].
In conclusion, given the great clinical relevance of 
strains that are heteroresistant to glycopeptides and 
the possible negative impact on treatment choices, it is 
important to draw up and implement infection control 
practices, including surveillance, the appropriate use of 
isolation precautions, staff training, hand hygiene, en-
vironmental cleansing and good antibiotic stewardship.
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